Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
174 studies found for:    "PDGFRA-associated chronic eosinophilic leukemia" OR "Hypereosinophilic Syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"PDGFRA-associated chronic eosinophilic leukemia" OR "Hypereosinophilic Syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: imatinib mesylate
2 Recruiting Compassionate Use of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES)
Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
3 Completed Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: SCH55700
4 Terminated
Has Results
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
5 Not yet recruiting Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Condition: Hypereosinophilic Syndrome
Interventions: Drug: Mepolizumab 300 mg;   Drug: Placebo matching mepolizumab;   Drug: Active OCS capsules (5 mg prednisolone or prednisone);   Drug: Placebo matching OCS capsules
6 Recruiting Imatinib Mesylate to Treat Myeloproliferative Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Imatinib Mesylate
7 Active, not recruiting Identification of New Markers in the Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Biological: biologie sample
8 Recruiting Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Intervention: Drug: Dexpramipexole
9 Recruiting Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Condition: Hypereosinophilic Syndrome
Interventions: Drug: benralizumab;   Other: Placebo
10 Completed Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia;   Chronic Idiopathic Hypereosinophilia
Intervention: Drug: Imatinib
11 Completed Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Conditions: Hypereosinophilia;   Hypereosinophilic Syndrome
Intervention: Drug: mepolizumab
12 Unknown  Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia (CEL);   Myeloproliferative Disorders
Intervention: Drug: STI571
13 Withdrawn Phase II Gleevec Idiopathic Hypereosinophilic Syndrome
Conditions: Eosinophilia;   Hypereosinophilic Syndrome
Intervention: Drug: Gleevec
14 Recruiting Eosinophilia Diagnosis
Condition: Hypereosinophilic Syndrome
Intervention: Other: Scheduled exams and diagnosis
15 Recruiting Steroid Treatment for Hypereosinophilic Syndrome
Condition: Hypereosinophilia
Intervention: Drug: Corticosteroids
16 Completed 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
Condition: Leukemia
Interventions: Drug: 2-CdA;   Drug: Ara-C;   Drug: G-CSF (Granulocyte colony-stimulating factor)
17 Completed Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Conditions: Hypereosinophilic Syndromes;   Eosinophilic Gastroenteritis;   Churg-Strauss Syndrome;   Eosinophilic Esophagitis
Intervention: Drug: Mepolizumab
18 Completed Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)
19 Active, not recruiting Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Agnogenic Myeloid Metaplasia;   Myelofibrosis;   Hypereosinophilic Syndrome;   Polycythemia Vera;   Mastocytosis;   Leukemia, Myelomonocytic, Chronic
Intervention: Drug: Dasatinib (BMS-354825)
20 Completed Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Conditions: Hypereosinophilic Syndrome;   Systemic Mastocytosis;   Chronic Myelomonocytic Leukemia;   Dermatofibrosarcoma
Intervention: Drug: imatinib mesylate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.